AstraZeneca finalized a $2 billion equity investment in Summit Therapeutics, taking a stake while launching clinical collaboration plans to test Summit’s ivonescimab with AstraZeneca’s antibody-drug conjugates. The investment is tied to combination trial development focused on cancer regimens that pair PD-1/VEGF signaling with ADC delivery. The agreement supports testing ivonescimab alongside AstraZeneca’s CLDN18.2-directed ADC in gastrointestinal cancers first, with broader combination exploration described across AstraZeneca’s ADC portfolio. The structure preserves separate development and commercial rights for each company’s assets. The deal follows earlier disclosed clinical signals for both ivonescimab and AstraZeneca’s ADCs, providing a rationale for pairing modalities where immunotherapy and cytotoxic payload delivery could complement each other. In market terms, AstraZeneca’s approach underscores how ADC combinations are increasingly becoming a financing and pipeline-integrating strategy rather than a purely standalone development path.